Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep1046 | Thyroid | ECE2022

Occult papillary thyroid carcinoma with lymphatic metastasis as first presentation of the disease - A report of two cases

Haxhiraj Adela , Cerma Adishah , Hoxha Violeta , Ylli Dorina , Ylli Agron

Introduction: Occult papillary carcinomas are small thyroid carcinomas (<1 cm) diagnosed after an initial manifestation of lymph nodes or distant metastasis. We report two cases of patients with this pattern of clinical presentation.Case description: The first case is a 21-year-old woman, with a one-year history of a growing cervical cyst. Fine needle aspiration of the cyst showed metastasis from papillary thyroid cancer. She had no previous history ...

ea0090p341 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Prevalence and Impact of Diabetes Mellitus in Adult Tuberculosis Patients;A Cross-Sectional Study

Xhardo Hysenbelli Elona , Hysenbelli Bledar , Ylli Dorina , Smaja Genta

Background: Both diabetes mellitus (DM) and tuberculosis (TB) are major public health problems and among the leading causes of morbidity and mortality worldwide. The TB-DM coexistence is known to complicate TB care, control and prevention. Globally, 10.4 million TB cases exists, of them 10 % are linked to DM. People with DM are at four to five times higher risk of getting infected with tuberculosis and evidence show poor TB treatment outcomes. This study purposed to evaluate t...

ea0035p1019 | Thyroid (non-cancer) | ECE2014

Oral solution of levothyroxine vs tablets in subclinical hypothyroidism: evaluation of outcomes

Pastore Renato , Mentuccia Daniela , Ylli Dorina , Ilaria Giordani , Simona Frontoni

Introduction: Oral levothyroxine (LT4) is the standard treatment for hypothyroidism and serum TSH represents the best marker for assessing the proper LT4 dose. The absorption and bioequivalence of different commercial LT4 preparations might be variable. The aim of this study is to compare the efficacy of levothyroxine oral solution vs tablets.Methods: Fifty-eight patients (six males, 52 females; average age, 46.9±12....

ea0032p97 | Bone and Osteoporosis | ECE2013

Change in bone mass in patients with established hyperthyroidism

Toti Florian , Ruci Dorina , Backa Teuta , Petrela Elizama

Objectives: To evaluate the presence and the degree of osteoporosis and osteopenia in a group of patients with established hyperthyroidism from at least 6 months.Material and methods: This study was based on a quantitative measurement of bone mineral density with and heel ultrasound densitometer (Type Pegassus). Each selected patient was recorded for the weight, height, BMI, age, and gender. No patient was previously treated for osteoporosis or osteopeni...

ea0056p416 | Diabetes complications | ECE2018

Comparitive angiographic profile in diabetic and non-diabetic patient (retrospective study)

Dyrmishi Blertina , Olldashi Taulant , Lumi Ema , Puca Entela , YLLI Dorina

Background: Diabetes is one of the risk factor for coronary disease. Patient with diabetes have a increased prevalence and incidence of coronary vessels disease compare with the people without diabetes in the general population.Aim and objectives: To compare the study of angiographic coronary results in the patient with and without diabetes.Materials and methods: 172 pacients; 66 with diabetes and 106 without diabetes was admitted ...

ea0056p801 | Pituitary - Clinical | ECE2018

Gonadotroph pituitary macroadenoma inducing ovarian hyperstimulation syndrome

Dyrmishi Blertina , Olldashi Taulant , Puca Entela , Lumi Ema , Ylli Dorina

Case report: We report a young woman with ovarian hyper stimulation syndrome (OHSS), headache, visual field defect and pituitary macro adenoma. The patient was treated about four years ago as pituitary PRL-secreting adenoma with carbergoline. The evaluation of other hormones FSH, LH and Estradiol values wasn’t done. The patient presented to our hospital with abdominal pain and headaches and amenohrrea. The pregnancy test was negative and pelcic ultrasound demonstrated enl...

ea0075d06 | Diabetes | EYES2021

Factors predisposing to diabetes onset in hospitalised COVID-19 patients

Cerma Adishah , Muja Ardita , Haxhiraj Adela , Ylli Dorina

Background: The presence of diabetes and the degree of hyperglycemia is considered an independent factor in the clinical severity of COVID-19 infection, impacting the duration of hospital stay and other related medical conditions.Objective: To identify the correlation between the insulin needs in COVID-19 patients and hospital stay and other related medical conditions. To identify the factors that would contribute to diabetes onset during COVID-19 infect...

ea0092ps1-02-06 | Graves’ Disease | ETA2023

The role of selenium supplement in graves disease - a case report

Haxhiraj Adela , Poshi Klodiana , Hoxha Violeta , Kermaj Marjeta , Ylli Dorina

Introduction: Selenium is a mineral that plays a key role in the intracellular reactions of the thyroid. Some selenium-based proteins have a protective antioxidant function in thyrocytes. Likewise, Selenium is incorporated into deiodinases, helping in the synthesis of thyroid hormones. Through its antioxidant and anti inflammatory properties, selenium affects the development of autoimmune thyroid diseases, such as Graves Disease. Supplementation with selenium is often prescrib...

ea0063p1125 | Reproductive Endocrinology 2 | ECE2019

Both comorbidity burden and low testosterone can explain symptoms and signs of testosterone deficiency in men consulting for sexual dysfunction

Rastrelli Giulia , Corona Giovanni , Maggi Mario

Background: Low testosterone (T) is frequent in men with chronical illnesses. The clinical features of T deficiency (TD) overlap with those of chronic diseases. The aim of this study is to evaluate the relative contribution of chronic disease score (CDS) and low T to the presence of TD symptoms.Methods: A consecutive series of 3862 men (aged 52.1±13.1 years) consulting for sexual dysfunction was studied. Several clinical and biochemical parameters w...

ea0035p286 | Clinical case reports Thyroid/Others | ECE2014

One month-Tadalafil 5 mg once daily administration improves clinical and ultrasound parameters of chronic pelvic pain syndrome/lower urinary tract symptoms

Lotti Francesco , Corona Giovanni , Maggi Mario

Introduction: Tadalafil 5 mg once daily (T5od) has been recently approved by the Food and Drug Administration for the treatment of lower urinary tract symptoms (LUTS), along with erectile dysfunction (ED). Recent pooled data analyses demonstrated that T5od–International Prostate Symptom Score related improvements were significant regardless of confounders. In addition, PDE5 inhibitors exert a positive effect on ejaculatory latency. We assessed the clinical outcome of 30 d...